Interventional Therapy Articles & Analysis
18 news found
Idiopathic pulmonary fibrosis (IPF) remains a devastating condition with limited treatment options, often leading to a grim prognosis. However, a recent study by Milman-Krentsis (2024) offers a beacon of hope, demonstrating the potential of lung cell transplantation as a therapeutic intervention for lung fibrosis. Utilizing two distinct mouse models—one treated with bleomycin and another ...
This progress highlights the potential for gene therapy to go beyond rare diseases and to address larger patient populations with significant unmet needs, such as chronic cardiovascular diseases. ...
Endocrine therapy can also be used as primary prevention in women at high risk for developing breast cancer. ...
ByBayer AG
Vascular embolization, performed by interventional radiologists, is an effective therapy for addressing the symptoms of patients suffering from this condition. ...
Based on the expedited animal- and cell-based models, professional mitochondrial functional assessment in vivo/in vitro, as well as the advanced analysis platform, the company can work with partners to validate and explore the pathogenesis of mitochondria-associated cardiac diseases and possible interventions. “To date, however, mitochondria-targeting therapies ...
“Continuous IOP monitoring represents the beginning of a paradigm shift towards evidence-based diagnostics for healthcare providers and payors who will see the economic value of earlier intervention in slowing vision loss and improving quality of life,” said Ariel Cao, president and CEO, Injectsense Inc. ...
This peer-reviewed article describes the design of the trial which investigated Lomecel-B, a living cell therapy product, as a regenerative medicine strategy for the treatment of frailty in older adults. ...
” The Furosemide Stress Test (FST) is commonly used in the critical care setting to gauge the likelihood that a patient with early-stage acute kidney injury will progress to more severe stages resulting in major, costly interventions that include readmissions, renal replacement therapy, permanent dialysis and mortality. ...
” InspireMD CEO, Marvin Slosman, added, “This milestone marks the beginning of what we consider to be the next step in our journey of establishing CGuard EPS as the leading stent device for treatment of CAD and the transition from surgical intervention to endovascular therapy. The U.S. market has been a priority for our company and we believe that ...
Braun and Nipro have worked together over the last decade to arm vascular specialists in Europe and Asia with alternative therapies for coronary interventions,” said Nozomu Fujita, President & CEO of Infraredx, a Nipro Company. ...
“The highest bar is needed to validate closed-loop SCS therapies, and I applaud the scientists and clinician researchers who have dedicated themselves to the advancement of new neuromodulation therapies in pain ...
” Solbiati added, “Histotripsy’s non-invasive approach and novel mechanical destruction of tumors provide potential for this procedure to become a leading technology in interventional therapies.” Joe Amaral, MD, HistoSonics’ Vice President of Medical Affairs, also commented, “I am excited to work with our co-Principal ...
It allows for medical professionals to rapidly assess the respiratory status of a patient, titrate interventions, and determine response to therapy. Providers do not have to introduce their patients to painful and invasive blood draws or radiation exposure. ...
The trial will enroll patients who are not responding to medication and are unsuitable for coronary artery bypass graft or percutaneous coronary intervention. XC001 is an investigational novel gene therapy designed to activate naturally occurring biological pathways to improve blood flow to areas of the heart not receiving adequate blood supply. ...
Leon, MD, professor of medicine and Director of the Center for Interventional Vascular Therapy at Columbia University Irving Medical Center and NewYorkPresbyterian, and chairman of the CorCinch-HF study. “The CorCinch clinical programs are developing a new class of therapy and the clinical trials have embraced a strong collaboration between ...
The new system features improvements in ease of use. PiCSO therapy is delivered by interventional cardiologists during the primary PCI (Percutaneous Coronary Intervention) procedure in patients experiencing anterior STelevated myocardial infarction (STEMI). ...
“This recognition reflects the significance and potential of the LIVE Therapy for the treatment of ischemic heart failure, the number-one cause of mortality worldwide. Designated by the FDA as a Breakthrough Device, the LIVE Therapy is the only option available commercially or in clinical trials that can less invasively exclude scar tissue on the left ...
The Centers for Medicare & Medicaid Services (CMS) also recently acknowledged the importance of this designation by establishing an alternative reimbursement pathway for products that receive FDA marketing authorization and held the Breakthrough Designation. PiCSO therapy is provided by interventional cardiologists during PCI (Percutaneous Coronary ...